caplacizumab   Click here for help

GtoPdb Ligand ID: 9123

Synonyms: ALX-0081 | anti-vWF Nanobody | Cablivi® | caplacizumab-yhdp
Approved drug
caplacizumab is an approved drug (EMA (2018), FDA (2019))
Compound class: Antibody
Comment: Caplacizumab (ALX-0081) is a nanobody targeting von Willebrand factor (vWF) [5], with anti-thrombotic action [1]. NanobodyTM technology was commercially developed by Ablynx. Nanobodies are antibody derivatives comprising only the single variable domains (variable heavy, VH) whilst retaining full antigen binding capacity. Their relatively small size (compared to complete antibodies) provides the potential for alternative modes of delivery and the possibility of brain penetrance.
Annotated peptide sequences for this therapeutuc are available from its IMGT/mAb-DB record. BLAST protein sequence analysis of the peptide sequence submitted with the INN document for caplacizumab reveals a 100% match with SEQ ID NO: 90 claimed in patent US7807162 [4], which is preferred humanized variant 12A2H1 in the patent document.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (EMA (2018), FDA (2019))
International Nonproprietary Names Click here for help
INN number INN
9511 caplacizumab
Synonyms Click here for help
ALX-0081 | anti-vWF Nanobody | Cablivi® | caplacizumab-yhdp
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 401
Other databases
GtoPdb PubChem SID 315661208
Search PubMed clinical trials caplacizumab
Search PubMed titles caplacizumab
Search PubMed titles/abstracts caplacizumab